Australia ↗
Australia separates TGA medicine registration from PBS subsidy. New formulations and funding recommendations can make headlines before a patient can obtain the treatment at a subsidised pharmacy price.
Read the country guide →Australia and New Zealand provide useful comparisons for UK readers following treatment-access news. TGA or Medsafe approval and PBS or Pharmac funding are separate milestones. Neither country's decisions change a medicine's UK licence or the NHS criteria that apply where you live.
An Australian PBAC recommendation is not itself a PBS listing. Likewise, a medicine on Pharmac's Options for Investment list is not yet publicly funded. Check the indication and effective date of any final funding decision.
An overseas approval can be a reason to ask about developments, but a UK clinician still needs UK product information and the relevant care pathway. We do not convert international private prices into claimed UK savings.
Australia separates TGA medicine registration from PBS subsidy. New formulations and funding recommendations can make headlines before a patient can obtain the treatment at a subsidised pharmacy price.
Read the country guide →New Zealand separates Medsafe approval from Pharmac funding. Pharmac's November 2026 update says Wegovy and Mounjaro remain unfunded. These decisions do not determine UK access.
Read the country guide →